Prostate Cancer Diagnostics Market Report 2026

Prostate Cancer Diagnostics Market Overview

• Prostate Cancer Diagnostics market size has reached to $5.02 billion in 2025 • Expected to grow to $9.19 billion in 2030 at a compound annual growth rate (CAGR) of 12.9% • Growth Driver: Global Surge In Prostate Cancer Cases Drives Expansion Of Prostate Cancer Diagnostics Market • Market Trend: Innovative Technological Advancements Propel Prostate Cancer Diagnostics Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Prostate Cancer Diagnostics Market?

Prostate cancer diagnostics refers to the process of determining and verifying the presence of prostate cancer using diagnostic testing and medical evaluations to evaluate the status and severity of the illness and direct treatment choices. It is commonly used to treat prostatic adenocarcinoma, transitional cell carcinomas, and neuroendocrine tumors. The main products of prostate cancer diagnostics are instruments, reagents and consumables, accessories. Accessories refer to items in the kit that are not typically necessary but can be used with or added to something else to make it more effective, a prostate-specific antigen (PSA) test kit, biopsy needle, and ultrasound gel are used in the diagnosis of prostate cancer. The various test types include preliminary tests and confirmatory tests that diagnose various prostate cancers such as squamous cell cancer, small cell carcinoma, transitional cell cancer, prostatic adenocarcinoma, ductal adenocarcinoma, small cell prostate cancer, acinar adenocarcinoma. These are used by various peer groups such as adult, pediatric, and geriatrics and also performed by various end users such as hospitals, independent diagnostic laboratories, cancer research institutes, others

What Is The Prostate Cancer Diagnostics Market Growth Forecast?

The prostate cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $9.19 billion in 2030 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to advancement of molecular and genomic diagnostics, rising adoption of precision oncology approaches, expansion of population screening initiatives, increasing investments in diagnostic automation, growing demand for personalized cancer diagnostics. Major trends in the forecast period include increasing adoption of advanced diagnostic assays, rising use of biomarker-based prostate cancer testing, growing integration of AI-assisted imaging analysis, expansion of early detection screening programs, enhanced focus on diagnostic accuracy and risk stratification.

Global Prostate Cancer Diagnostics Market Segmentation

1) By Products: Instruments, Reagents And Consumables, Accessories 2) By Test Type: Preliminary Tests, Confirmatory Tests 3) By Prostate Cancer: Squamous Cell Cancer, Small Cell Carcinoma, Transitional Cell Cancer, Prostatic Adenocarcinoma, Ductal Adenocarcinoma, Small Cell Prostate Cancer, Acinar Adenocarcinoma 4) By Peer Groups: Adult, Geriatrics 5) By End User: Hospitals, Independent Diagnostic Laboratories, Cancer Research Institutes, Other End-Users Subsegments: 1) By Instruments: Biopsy Instruments, Imaging Devices, Digital Rectal Examination Tools 2) By Reagents And Consumables: Diagnostic Assay Kits, Staining Reagents, Sample Collection Materials 3) By Accessories: Biopsy Guides, Specimen Handling Accessories, Calibration And Maintenance Tools

What Is The Driver Of The Prostate Cancer Diagnostics Market?

The increasing prevalence of prostate cancer is expected to propel the growth of the prostate cancer diagnostics market going forward. Prostate cancer is a condition in which cancer arises in the prostate gland, a component of the male and female reproductive systems. Prostate cancer diagnostics help patients to diagnose the disease early with various tests, including prostate-specific antigen (PSA) testing and sophisticated imaging techniques. For instance, in January 2023, according to the American Cancer Society (ACS), a US-based non-profit organization dedicated to eliminating cancer, approximately 288,300 new cases of prostate cancer and 34,700 deaths attributed to prostate cancer in 2023. Therefore, the increasing prevalence of prostate cancer is expected to propel the growth of the prostate cancer diagnostics industry.

Key Players In The Global Prostate Cancer Diagnostics Market

Major companies operating in the prostate cancer diagnostics market are F Hoffmann La Roche AG, Bayer AG, Thermo Fisher Scientific Inc, Abbott Laboratories Inc, Siemens Healthineers AG, Becton Dickinson And Company, Agilent Technologies Inc, Hologic Inc, bioMerieux SA, Beckman Coulter Inc, Qiagen NV, Exact Sciences Corporation, DiaSorin SpA, OPKO Health Inc, Myriad Genetics Inc, Cepheid Inc, NeoGenomics Laboratories Inc, Fujirebio Diagnostics Inc, Ambry Genetics Corporation, MDxHealth SA, Exosome Diagnostics Inc, Cellanyx Diagnostics Inc, A3P Biomedical AB, Roche Diagnostics GmbH, Sysmex Corporation

Global Prostate Cancer Diagnostics Market Trends and Insights

Major companies operating in the prostate cancer diagnostics market are focusing on developing advanced AI-powered solutions to improve diagnostic accuracy, reduce interpretation time, and support early detection of prostate cancer. AI-powered prostate cancer diagnosis tools utilize machine learning algorithms to identify prostatic adenocarcinoma regions and analyze whole slide images of prostate core needle biopsies, assisting pathologists in delivering accurate and timely diagnoses. For instance, in March 2023, Qritive, a Singapore-based company specializing in diagnostic technologies, launched QAi Prostate, an advanced AI-driven prostate cancer diagnosis tool for pathologists. The solution helps streamline workflow, enhances diagnostic precision, and reduces the time required for treatment planning.

What Are Latest Mergers And Acquisitions In The Prostate Cancer Diagnostics Market?

In October 2024, Trinity Biotech plc, an Ireland-based provider of in vitro diagnostics and diabetes management diagnostic products, acquired Epicapture Limited for an undisclosed amount. With this acquisition, Trinity aimed to enter the oncology diagnostics market by integrating a non-invasive, epigenetic prostate cancer monitoring test into its product portfolio. EpiCapture Limited is an Ireland-based company developing a urine-based epigenetic DNA methylation test for assessing the risk of aggressive prostate cancer.

Regional Outlook

North America was the largest region in the prostate cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Prostate Cancer Diagnostics Market?

The prostate cancer diagnostics market consists of revenues earned by entities by providing transrectal ultrasound, magnetic resonance imaging (MRI), and computerized tomography (CT) scans. The market value includes the value of related goods sold by the service provider or included within the service offering. The prostate cancer diagnostics market also includes sales of products such as tumor biopsies, and test kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Prostate Cancer Diagnostics Market Report 2026?

The prostate cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the prostate cancer diagnostics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.